Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

The Final Results of a Phase I Study Using Bortezomib (Velcade), Cladribine, and Rituximab (VCR) in Treating Mantle Cell Lymphoma

Jeffrey J. Pu, Kristin Berger, Chunlei Zheng, Nhan V Do, David F. Claxton, W Christopher Ehmann, Joseph J. Drabick, Thomas P. Loughran, Jr., Elliot Epner

Blood (2023) 142 (Supplement 1): 6152.

https://doi.org/10.1182/blood-2023-185797

Published: 2023

Journal Articles

Viridans Group Streptococcal Bacteremia after Allogeneic Stem Cell Transplant with Post-Transplant Cyclophosphamide

Blood (2022) 140 (Supplement 1): 7589–7590.

https://doi.org/10.1182/blood-2022-167227

Published: 2022

Journal Articles

Engraftment Kinetics and Recipient Chimerism Increase to Predict Leukemia Relapse By Ptcy and Non-Ptcy Transplant

Ruoheng Zhang, Kevin L Rakszawski, Myles Nickolich, W. Christopher Ehmann, Baldeep Wirk, Seema G Naik, Witold B. Rybka, Hong Zheng, Joseph Mierski, Brooke Silar, Gina Mackey, Jason Liao, Shouhao Zhou, Robert Greiner, Valerie Brown, David F. Claxton, Shin Mineishi, Hiroko Shike, Kentaro Minagawa

Blood (2021) 138 (Supplement 1): 1792.

https://doi.org/10.1182/blood-2021-148872

Published: 2021

Journal Articles

Long Term Follow up of the Resort Study (E4402): A Randomized Phase III Study Comparing Two Different Rituximab Dosing Strategies for Low Tumor Burden Follicular Lymphoma

Brad S. Kahl, Fangxin Hong, Christopher Peterson, Lode J. Swinnen, Thomas M. Habermann, Stephen J Schuster, Matthias Weiss, Paul A S Fishkin, W. Christopher Ehmann, Timothy S. Fenske, Michael E. Williams

Blood (2021) 138 (Supplement 1): 815.

https://doi.org/10.1182/blood-2021-152976

Published: 2021

Journal Articles

Effect of Avelumab to Immune Response in AML: A Phase I Study of Avelumab in Combination with Decitabine As First Line Treatment of Unfit Patients

Hong Zheng, MD PhD, Shin Mineishi, David F. Claxton, MD, Junjia Zhu, Chenchen Zhao, MD, Bei Jia, MD PhD, W. Christopher Ehmann, MD, Seema Naik, MD, Natthapol Songdej, Raymond J. Hohl

Blood (2019) 134 (Supplement_1): 3939.

https://doi.org/10.1182/blood-2019-125153

Published: 2019

Journal Articles

Non-Myeloablative Allogeneic Stem Cell Transplant in Acute Myeloid Leukemia: Graft-Versus-Host Disease Potentiates Graft-Versus-Leukemia Effect and Improves Overall Survival

Christopher J Pizzola, MD MPH, Kevin L Rakszawski, MD, W. Christopher Ehmann, MD, Witold B. Rybka, MD, Baldeep Wirk, MD, Seema Naik, MD, Hong Zheng, MD PhD, Brook Silar, Gina Mackey, CCRP, Shin Mineishi, MD, Kentaro Minagawa, MD PhD, David F. Claxton, MD

Blood (2019) 134 (Supplement_1): 5724.

https://doi.org/10.1182/blood-2019-128817

Published: 2019

Journal Articles

TIGIT Expression Positively Associates with NK Cell Function in AML Patients

Bei Jia, MD PhD, Chenchen Zhao, MD, David F. Claxton, MD, W. Christopher Ehmann, MD, Witold B. Rybka, Shin Mineishi, Seema Naik, Natthapol Songdej, Muhammad Khawaja, Raymond J. Hohl, Hong Zheng, MD PhD

Blood (2018) 132 (Supplement 1): 5250.

https://doi.org/10.1182/blood-2018-99-113578

Published: 2018

Journal Articles

The Mantle Cell Lymphoma Response to VCR Protocol Associated with Its Sensitivity to Hypomethylation Regulation-a Collateral Study on VCR Phase I Trial

Jeffrey J Pu, MD PhD, Matthew Nemesure, W. Christopher Ehmann, MD, David F Claxton, MD, Joseph J Drabick, MD, Anna C Salzberg, Yuka I Kawasawa, PhD, Elliot Epner, MD PhD

Blood (2018) 132 (Supplement 1): 5295.

https://doi.org/10.1182/blood-2018-99-118192

Published: 2018

Journal Articles

Multi-Dimensional Analysis of Immune Signature Predicts Response to Decitabine Treatment in Elderly Patients with AML

Chenchen Zhao, MD, Bei Jia, MD PhD, Liru Wang, David F. Claxton, MD, W. Christopher Ehmann, MD, Witold B. Rybka, Shin Mineishi, Seema Naik, Natthapol Songdej, Muhammad Khawaja, Raymond J. Hohl, Hong Zheng, MD PhD

Blood (2018) 132 (Supplement 1): 1526.

https://doi.org/10.1182/blood-2018-99-113547

Published: 2018

Journal Articles

Impact of Ruxolitinib in Myelofibrosis Allogeneic Stem Cell Transplant Outcome---a Pilot Study

Joyson Poulose, MD, Jozef Malysz, MD, David F Claxton, MD, W. Christopher Ehmann, Shin Mineishi, Witold B. Rybka, Raymond J. Hohl, Jeffrey J Pu, MDPhD

Blood (2017) 130 (Supplement 1): 5543.

https://doi.org/10.1182/blood.V130.Suppl_1.5543.5543

Published: 2017

Journal Articles

Eomes + T-bet int CD8 T Cells Are Functionally Impaired and Associate with Primary Refractory Disease in Patients with Acute Myeloid Leukemia (AML)

Bei Jia, MD PhD, David F. Claxton, W. Christopher Ehmann, Witold B. Rybka, Shin Mineishi, Liru Wang, Todd D. Schell, Raymond J. Hohl, Hong Zheng, MDPhD

Blood (2017) 130 (Supplement 1): 108.

https://doi.org/10.1182/blood.V130.Suppl_1.108.108

Published: 2017

Journal Articles

Bone Marrow CD8 T Cells Express High Frequency of PD-1 and Exhibit Reduced Anti-Leukemia Response in AML Patients

Bei Jia, MD PhD, Liru Wang, David F. Claxton, W. Christopher Ehmann, Witold B. Rybka, Shin Mineishi, Hiroko Shike, Michael Bayerl, Todd D. Schell, Raymond J. Hohl, Hong Zheng, MDPhD

Blood (2017) 130 (Supplement 1): 3946.

https://doi.org/10.1182/blood.V130.Suppl_1.3946.3946

Published: 2017

Journal Articles

The Results of a Phase I Study using Velcade (Bortezomib), Cladribine, and Rituximab (VCR) in treating Mantle Cell Lymphoma

Jeffrey J. Pu, MD PhD, W. Christopher Ehmann, MD, Jason Liao, PhD, Christine Capper, BSN, Michelle Levy, MD, David F. Claxton, MD, Witold B. Rybka, MD, Raymond J. Hohl, MD PhD, Elliot M. Epner, MD PhD

Blood (2016) 128 (22): 1792.

https://doi.org/10.1182/blood.V128.22.1792.1792

Published: 2016

Journal Articles

Utilization of Total Body Irradiation Is Not Necessary for Unrelated Donor Umbilical Cord Blood Transplants: a Single-Center Experience

Jeffrey J. Pu, MD PhD, Elizabeth L Miller, Arthur Berg, PhD, Melanie Comito, Robert J. Greiner, MD, W. Christopher Ehmann, MD, David F. Claxton, MD, Witold B Rybika

Blood (2014) 124 (21): 5844.

https://doi.org/10.1182/blood.V124.21.5844.5844

Published: 2014

Journal Articles

Early Discharge and Out Patient Management After AML Induction Chemotherapy: Determinants of Safety

Roberto A Ferro, MD, Junjia Zhu, Ph.D, W. Christopher Ehmann, MD, Susan Rokita, CRNP, MSN, Vicki Haight, CRNP, MSN, Jo Ann Davidson, CRNP, MSN, Constance Berk, PA-C, Witold Rybka, MD, David F. Claxton, MD

Blood (2012) 120 (21): 2054.

https://doi.org/10.1182/blood.V120.21.2054.2054

Published: 2012

Journal Articles

Inotuzumab Ozogamicin (CMC-544) In Patients with Indolent B-Cell NHL That Is Refractory to Rituximab Alone, Rituximab and Chemotherapy, or Radioimmunotherapy: Preliminary Safety and Efficacy From a Phase 2 Trial

Andre Goy, MD, Joseph Leach, MD, W. Christopher Ehmann, MD, Kiyoshi Ando, MD, PhD, Kiyohiko Hatake, MD, PhD, Kensei Tobinai, MD, PhD, Tatyana Feldman, MD, Steven Hua, Angela DG Volkert, Erik R. Vandendries, MD, PhD, Michinori Ogura, MD, PhD

Blood (2010) 116 (21): 430.

https://doi.org/10.1182/blood.V116.21.430.430

Published: 2010

Journal Articles

Clofarabine, Etoposide and Mitoxantrone In the Therapy of Relapsed and Refractory Acute Myelogenous Leukemia

W. Christopher Ehmann, MD, Sulfikar Ibrahim, MD, Witold Rybka, MD, David F. Claxton, MD

Blood (2010) 116 (21): 4353.

https://doi.org/10.1182/blood.V116.21.4353.4353

Published: 2010

Journal Articles

Fludarabine-Associated Acute Promyelocytic Leukemia

Clayton B Hess, BA, W. Christopher Ehmann, MD

Blood (2010) 116 (21): 4383.

https://doi.org/10.1182/blood.V116.21.4383.4383

Published: 2010

Journal Articles

Sirolimus for Graft-Versus-Host-Diseases Prophylaxis in Non-Myeloablative Matched Related Transplantation: Safety and Efficacy.

Hong Zheng, MD, PhD, Michelle Carraher, BA, Eric Schaefer, M.A., Giampaolo Talamo, MD, W. Christopher Ehmann, MD, Witold Rybka, David F. Claxton, M.D.

Blood (2009) 114 (22): 4329.

https://doi.org/10.1182/blood.V114.22.4329.4329

Published: 2009

Journal Articles

Identification of a Second Acute Promyelocytic Leukemia (APL) Patient with the STAT5b-RARα Fusion Gene among PML-RARα-Negative Eastern Cooperative Oncology Group (ECOG) APL Protocol Registrants.

Robert E. Gallagher, MD, Serena Mak, BA, Elisabeth Paietta, PhD, Brenda Cooper, MD, W. Christopher Ehmann, MD, Martin S. Tallman, MD

Blood (2004) 104 (11): 3005.

https://doi.org/10.1182/blood.V104.11.3005.3005

Published: 2004

NARROW

The Final Results of a Phase I Study Using Bortezomib (Velcade), Cladribine, and Rituximab (VCR) in Treating Mantle Cell Lymphoma

Viridans Group Streptococcal Bacteremia after Allogeneic Stem Cell Transplant with Post-Transplant Cyclophosphamide

Engraftment Kinetics and Recipient Chimerism Increase to Predict Leukemia Relapse By Ptcy and Non-Ptcy Transplant

Long Term Follow up of the Resort Study (E4402): A Randomized Phase III Study Comparing Two Different Rituximab Dosing Strategies for Low Tumor Burden Follicular Lymphoma

Effect of Avelumab to Immune Response in AML: A Phase I Study of Avelumab in Combination with Decitabine As First Line Treatment of Unfit Patients

Non-Myeloablative Allogeneic Stem Cell Transplant in Acute Myeloid Leukemia: Graft-Versus-Host Disease Potentiates Graft-Versus-Leukemia Effect and Improves Overall Survival

TIGIT Expression Positively Associates with NK Cell Function in AML Patients

The Mantle Cell Lymphoma Response to VCR Protocol Associated with Its Sensitivity to Hypomethylation Regulation-a Collateral Study on VCR Phase I Trial

Multi-Dimensional Analysis of Immune Signature Predicts Response to Decitabine Treatment in Elderly Patients with AML

Impact of Ruxolitinib in Myelofibrosis Allogeneic Stem Cell Transplant Outcome---a Pilot Study

Eomes + T-bet int CD8 T Cells Are Functionally Impaired and Associate with Primary Refractory Disease in Patients with Acute Myeloid Leukemia (AML)

Bone Marrow CD8 T Cells Express High Frequency of PD-1 and Exhibit Reduced Anti-Leukemia Response in AML Patients

The Results of a Phase I Study using Velcade (Bortezomib), Cladribine, and Rituximab (VCR) in treating Mantle Cell Lymphoma

Utilization of Total Body Irradiation Is Not Necessary for Unrelated Donor Umbilical Cord Blood Transplants: a Single-Center Experience

Early Discharge and Out Patient Management After AML Induction Chemotherapy: Determinants of Safety

Inotuzumab Ozogamicin (CMC-544) In Patients with Indolent B-Cell NHL That Is Refractory to Rituximab Alone, Rituximab and Chemotherapy, or Radioimmunotherapy: Preliminary Safety and Efficacy From a Phase 2 Trial

Clofarabine, Etoposide and Mitoxantrone In the Therapy of Relapsed and Refractory Acute Myelogenous Leukemia

Fludarabine-Associated Acute Promyelocytic Leukemia

Sirolimus for Graft-Versus-Host-Diseases Prophylaxis in Non-Myeloablative Matched Related Transplantation: Safety and Efficacy.

Identification of a Second Acute Promyelocytic Leukemia (APL) Patient with the STAT5b-RARα Fusion Gene among PML-RARα-Negative Eastern Cooperative Oncology Group (ECOG) APL Protocol Registrants.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only